Saad Mysa, Spurr Alison, Lipson Jennifer
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Division of Dermatology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231160927. doi: 10.1177/2050313X231160927. eCollection 2023.
Pityriasis rubra pilaris is a rare inflammatory dermatosis characterized by orange-red confluent plaques, hyperkeratotic follicular papules, palmoplantar keratoderma, and, in some cases, erythroderma. The etiology of pityriasis rubra pilaris is unclear. This condition is often treated with oral retinoids and topical corticosteroids, and more recently, biological agents have become the mainstay of treatment. However, there is a paucity of high-quality evidence on the safety and effectiveness of these agents, and the disease often remains refractory to therapy. Herein, we present a case of pityriasis rubra pilaris with a favorable response to treatment with upadacitinib, a Janus kinase inhibitor, which has not been previously reported in the literature for the management of this condition.
红皮病型毛发红糠疹是一种罕见的炎症性皮肤病，其特征为橙红色融合斑块、角化过度的毛囊丘疹、掌跖角化病，在某些情况下还会出现红皮病。毛发红糠疹的病因尚不清楚。这种疾病通常用口服维甲酸和外用皮质类固醇治疗，最近，生物制剂已成为主要的治疗手段。然而，关于这些药物的安全性和有效性，高质量证据匮乏，而且该疾病往往对治疗难治。在此，我们报告一例红皮病型毛发红糠疹患者，使用Janus激酶抑制剂乌帕替尼治疗取得了良好疗效，此前文献中尚未报道过该药用于治疗这种疾病。
